These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
165 related items for PubMed ID: 38622211
1. Empagliflozin in children with glycogen storage disease-associated inflammatory bowel disease: a prospective, single-arm, open-label clinical trial. Li Z, Zhang X, Chen H, Zeng H, Wu J, Wang Y, Ma N, Lan J, Zhang Y, Niu H, Shang L, Jiang X, Yang M. Sci Rep; 2024 Apr 15; 14(1):8630. PubMed ID: 38622211 [Abstract] [Full Text] [Related]
2. Improved inflammatory bowel disease, wound healing and normal oxidative burst under treatment with empagliflozin in glycogen storage disease type Ib. Grünert SC, Elling R, Maag B, Wortmann SB, Derks TGJ, Hannibal L, Schumann A, Rosenbaum-Fabian S, Spiekerkoetter U. Orphanet J Rare Dis; 2020 Aug 24; 15(1):218. PubMed ID: 32838757 [Abstract] [Full Text] [Related]
3. Treatment recommendations for glycogen storage disease type IB- associated neutropenia and neutrophil dysfunction with empagliflozin: Consensus from an international workshop. Grünert SC, Derks TGJ, Mundy H, Dalton RN, Donadieu J, Hofbauer P, Jones N, Uçar SK, LaFreniere J, Contreras EL, Pendyal S, Rossi A, Schneider B, Spiegel R, Stepien KM, Wesol-Kucharska D, Veiga-da-Cunha M, Wortmann SB. Mol Genet Metab; 2024 Mar 24; 141(3):108144. PubMed ID: 38277989 [Abstract] [Full Text] [Related]
4. Clinical spectrum, over 12-year follow-up and experience of SGLT2 inhibitors treatment on patients with glycogen storage disease type Ib: a single-center retrospective study. Shao YX, Liang CL, Su YY, Lin YT, Lu ZK, Lin RZ, Zhou ZZ, Zeng CH, Tao CY, Liu ZC, Zhang W, Liu L. Orphanet J Rare Dis; 2024 Apr 11; 19(1):155. PubMed ID: 38605407 [Abstract] [Full Text] [Related]
5. Impact of genotype on neutropenia in a large cohort of Serbian patients with glycogen storage disease type Ib. Sarajlija A, Djordjevic M, Kecman B, Skakic A, Pavlovic S, Pasic S, Stojiljkovic M. Eur J Med Genet; 2020 Mar 11; 63(3):103767. PubMed ID: 31536830 [Abstract] [Full Text] [Related]
6. Crohn disease-like enterocolitis remission after empagliflozin treatment in a child with glycogen storage disease type Ib: a case report. Rossi A, Miele E, Fecarotta S, Veiga-da-Cunha M, Martinelli M, Mollica C, D'Armiento M, Mozzillo E, Strisciuglio P, Derks TGJ, Staiano A, Parenti G. Ital J Pediatr; 2021 Jul 02; 47(1):149. PubMed ID: 34215305 [Abstract] [Full Text] [Related]
7. Efficacy and safety of empagliflozin in glycogen storage disease type Ib: Data from an international questionnaire. Grünert SC, Derks TGJ, Adrian K, Al-Thihli K, Ballhausen D, Bidiuk J, Bordugo A, Boyer M, Bratkovic D, Brunner-Krainz M, Burlina A, Chakrapani A, Corpeleijn W, Cozens A, Dawson C, Dhamko H, Milosevic MD, Eiroa H, Finezilber Y, Moura de Souza CF, Garcia-Jiménez MC, Gasperini S, Haas D, Häberle J, Halligan R, Fung LH, Hörbe-Blindt A, Horka LM, Huemer M, Uçar SK, Kecman B, Kilavuz S, Kriván G, Lindner M, Lüsebrink N, Makrilakis K, Mei-Kwun Kwok A, Maier EM, Maiorana A, McCandless SE, Mitchell JJ, Mizumoto H, Mundy H, Ochoa C, Pierce K, Fraile PQ, Regier D, Rossi A, Santer R, Schuman HC, Sobieraj P, Spenger J, Spiegel R, Stepien KM, Tal G, Tanšek MZ, Torkar AD, Tchan M, Thyagu S, Schrier Vergano SA, Vucko E, Weinhold N, Zsidegh P, Wortmann SB. Genet Med; 2022 Aug 02; 24(8):1781-1788. PubMed ID: 35503103 [Abstract] [Full Text] [Related]
8. Case report: The success of empagliflozin therapy for glycogen storage disease type 1b. Klinc A, Groselj U, Mlinaric M, Homan M, Markelj G, Mezek Novak A, Sirca Campa A, Sikonja J, Battelino T, Zerjav Tansek M, Drole Torkar A. Front Endocrinol (Lausanne); 2024 Aug 02; 15():1365700. PubMed ID: 38919482 [Abstract] [Full Text] [Related]
9. Understanding the role of SGLT2 inhibitors in glycogen storage disease type Ib: the experience of one UK centre. Halligan RK, Dalton RN, Turner C, Lewis KA, Mundy HR. Orphanet J Rare Dis; 2022 May 12; 17(1):195. PubMed ID: 35549996 [Abstract] [Full Text] [Related]
10. Treating neutropenia and neutrophil dysfunction in glycogen storage disease type Ib with an SGLT2 inhibitor. Wortmann SB, Van Hove JLK, Derks TGJ, Chevalier N, Knight V, Koller A, Oussoren E, Mayr JA, van Spronsen FJ, Lagler FB, Gaughan S, Van Schaftingen E, Veiga-da-Cunha M. Blood; 2020 Aug 27; 136(9):1033-1043. PubMed ID: 32294159 [Abstract] [Full Text] [Related]
12. Genetic characterization of GSD I in Serbian population revealed unexpectedly high incidence of GSD Ib and 3 novel SLC37A4 variants. Skakic A, Djordjevic M, Sarajlija A, Klaassen K, Tosic N, Kecman B, Ugrin M, Spasovski V, Pavlovic S, Stojiljkovic M. Clin Genet; 2018 Feb 27; 93(2):350-355. PubMed ID: 28685844 [Abstract] [Full Text] [Related]
14. CRISPR/Cas9 genome editing of SLC37A4 gene elucidates the role of molecular markers of endoplasmic reticulum stress and apoptosis in renal involvement in glycogen storage disease type Ib. Skakic A, Andjelkovic M, Tosic N, Klaassen K, Djordjevic M, Pavlovic S, Stojiljkovic M. Gene; 2019 Jun 30; 703():17-25. PubMed ID: 30951856 [Abstract] [Full Text] [Related]
15. Novel SLC37A4 Mutations in Korean Patients With Glycogen Storage Disease Ib. Choi R, Park HD, Ko JM, Lee J, Lee DH, Hong SJ, Ki CS, Lee SY, Kim JW, Song J, Choe YH. Ann Lab Med; 2017 May 30; 37(3):261-266. PubMed ID: 28224773 [Abstract] [Full Text] [Related]
20. Successful use of empagliflozin to treat neutropenia in two G6PC3-deficient children: Impact of a mutation in SGLT5. Boulanger C, Stephenne X, Diederich J, Mounkoro P, Chevalier N, Ferster A, Van Schaftingen E, Veiga-da-Cunha M. J Inherit Metab Dis; 2022 Jul 30; 45(4):759-768. PubMed ID: 35506446 [Abstract] [Full Text] [Related] Page: [Next] [New Search]